Monday, July 10, 2006

Alder Biopharmaceuticals Raises $16M

Bothwell, Washington-based Alder Biopharmaceuticals has raised a round of venture capital funding. Alder said today that it has closed a $16M Series B funding from H.I.G. Ventures, along with existing investors Sevin Rosen Funds, Ventures West, and WRF Capital. Alder is developing antibody technologies targeted toward autoimmune and inflammatory disease. Aaron Davidson of H.I.G. Ventures joins the company's board as part of the funding. More information »